Skip to main content

Table 1 Immunotherapies for NPC treatment

From: Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment

Target Effects Treatment NCT number
PD-1 Bypass immune checkpoint Nivolumab, Pembrolizumab, Toripalimab, Penpulimab, Camrelizumab, Sintilimab, Tislelizumab, Treprilimab, SHR-1701 NCT02054806 [7], NCT02339558 [40], NCT02915432 [116], NCT03581786 [6], NCT03558191, NCT03267498, NCT03544099, NCT03734809, NCT03707509, NCT03925090, NCT03924986, NCT04282070, NCT04376866, NCT04447612, NCT04421469, NCT04534855, NCT04736810, NCT04833257, NCT04917770, NCT04944914, NCT04978012, NCT3707509, NCT05020925, NCT05097209, NCT05341193
PD-L1 Bypass immune checkpoint SHR-1701, Avelumab NCT04282070, NCT05020925, NCT04562441
CTLA-4 & PD-1 Bypass immune checkpoint Ipilimumab, AK104, IBI310 NCT03097939, NCT04220307, NCT04945421
LMP2 Direct cytotoxicity LMP2 Antigen-specific TCR T cell NCT03925896
EBV Direct cytotoxicity Autologous EBV specific Cytotoxic T cell NCT03648697, NCT02287311, NCT02578641 [117]
TGF-β Direct cytotoxicity TGF-β Resistant CTLs NCT02065362
  1. Abbreviations: CTLA-4 Cytotoxic T-lymphocyte antigen 4, PD-1 Programmed death 1, PD-L1 Programmed death ligand 1, CAR Chimeric antigen receptor